Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer

Jin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti et al. · 2010

Read Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer by Jin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010630.txt.

Introduction

Jin-Hyeok Hwang and colleagues searched for a marker that predicts chemotherapy success in pancreatic cancer, in PLOS ONE in 2010. Surgery can remove the tumor, yet the cancer often returns. Added drug treatment helps some patients and only burdens others.

The team measured a tiny molecule, microRNA-21, in tumor samples. Patients with high levels fared worse and gained less from added treatment. Low levels marked a group that benefited more. A simple tumor test of this kind could spare some patients harsh drugs that would not help them, and focus care where it works.

Catalog record

CREATORJin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010630

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer Authors: Jin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, Seth M. Steinberg, Leticia G. Leon, Yong-Tae Kim, Niccola Funel, Joo Kyung Park, Min A. Kim, Gyeong Hoon Kang, Sun-Whe Kim, Marco Del Chiaro, Godefridus J. Peters, Giuseppe Giaccone Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0010630 ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high risk of recurrence following surgical resection provides the rationale for adjuvant therapy. However, only a subset of patients benefit from adjuvant therapy. Identification of molecular markers to predict treatment outcome is therefore warranted. The aim of the present study was to evaluate whether expression of novel candidate biomarkers, including microRNAs, can predict clinical outcome in PDAC patients treated with adjuvant therapy. Formalin-fixed paraffin embedded specimens from a cohort of 82 resected Korean PDAC cases were analyzed for protein expression by immunohistochemistry and for microRNA expression using quantitative Real-Time PCR. Cox proportional hazards model analysis in the subgroup of patients treated with adjuvant therapy (N = 52) showed that lower than median miR-21 expression was associated with a significantly lower hazard ratio (HR) for death (HR = 0.316; 95%CI = 0.166–0.600; P = 0.0004) and recurrence (HR = 0.521; 95%CI = 0.280–0.967; P = 0.04). MiR-21 expression status emerged as the single most predictive biomarker for treatment outcome among all 27 biological and 9 clinicopathological factors evaluated. No significant association was detected in patients not treated with adjuvant therapy. In an independent validation cohort of 45 frozen PDAC tissues from Italian cases, all treated with adjuvant therapy, lower than median miR-21 expression was confirmed to be correlated with longer overall as well as disease-free survival. Furthermore, transfection with anti-miR-21 enhanced the chemosensitivity of PDAC cells. Low miR-21 expression was associated with benefit from adjuvant treatment in two independent cohorts of PDAC cases, and anti-miR-21 increased anticancer drug activity in vitro . These data provide evidence that miR-21 may allow stratification for adjuvant therapy, and represents a new potential target for therapy in PDAC. INTRODUCTION Pancreatic cancer is the fourth leading cause of cancer related death and over the last decades little improvement in survival has been observed despite extensive research efforts [1] . About 95% of exocrine pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC), of which incidence has risen steadily over the last decades [1] , [2] . Surgery is feasible in 15–20% of patients but, even after complete resection, prognosis remains dismal, with a 5-year survival rate lagging at 10–20% [3] . Pancreatic cancer is notoriously resistant to chemotherapy and radiotherapy. Adjuvant treatment is modestly effective and can have substantial toxicities. Therefore, the role of adjuvant therapy in resectable pancreatic cancer is still unclear, though generally thought to benefit a subset of patients [4] , [5] . Being able to identify this subset would be a great advance in the management of this disease as it would allow patient stratification for adjuvant treatment [6] . Therefore, predictive markers of sensitivity to adjuvant therapy as well as new therapeutic targets are urgently needed in this disease [7] , [8] . Altered expression of several factors has been associated with PDAC aggressive behaviour and prognosis. For example, among all cancers, PDAC has the highest frequency of K-Ras mutations, which has led to speculation regarding its application as a diagnostic as well as a prognostic marker [7] . The protein product of K-Ras is a GTP-binding protein mediating a number of critical cellular functions, including proliferation, cell survival and motility. However, most of the evidence, so far, suggests that K-ras mutations are not significantly associated with survival in pancreatic cancer patients [9] , [10] . Other studies suggested the prognostic significance of altered expression of proteins involved in the Ras signaling pathway, such as Akt. Nevertheless, phosphorylated Akt expression levels were associated with both shorter and longer survival in resectable PDAC patients [11] , [12] . Other markers reported as independent predictors of PDAC prognosis include p16, matrix metalloproteinase 7 (MMP-7) and vascular endothelial growth factor (VEGF) expression [13] . Still, many biological aspects governing this disease are still poorly understood and no single marker has been shown to accurately predict clinical outcome. In recent years, it has become clear that protein expression can also be regulated by microRNAs (miRNAs) [14] . MicroRNAs are a class of small non-coding RNAs that interact with the mRNAs of coding genes to direct their posttranscriptional repression [15] . MicroRNA have been shown to be involved in oncogenesis and tumor growth, and also to play a major role in chemoresistance [16] – [19] . Furthermore, the expression of microRNAs is tissue specific, and certain cancer histotypes can be classified based on microRNA expression profiles [20] , [21] . In pancreatic cancer, several miRNAs have been reported to be aberrantly expressed, including microRNAs with key roles in cancer, such as “onco(genic)-miRs”, miR-21 and miR-155, and “tumor suppressor miRs”, miR-29b and the miR-34 and Let-7 families [22] – [29] . Preclinical studies in PDAC cells showed that exogenous miR-34 overexpression was associated with reconstitution of p53-dependent tumor suppressor function in p53-deficient cells as well as inhibition of pancreatic cancer stem cell self-renewal [30] . Up-regulation of Let-7 is associated with reversal of epithelial to mesenchymal transition (EMT) in gemcitabine-resistant cells [31] . MicroRNA-29b can target de novo DNA methyltransferase 3A and 3B (DNMT3A and DNMT3B) and lead to global hypomethylation and overexpression of various tumor suppressor genes, including p16 [32] . MicroRNA-21 expression is associated with increased proliferation, invasive properties, and gemcitabine chemoresistance and a previous study showed that high miR-21 expression, as determined by in situ hybridization, was predictive of shorter survival in PDAC node-negative patients [28] , [33] . MicroRNA-155 is involved in the repression of Tumor protein 53-induced nuclear protein 1 , which is a proapoptotic stress-induced p53 target gene and a negative prognostic effect of high miR-155 expression was observed in a cohort of PDAC cases including patients with advanced disease and/or local R2-resection [34] , [35] . The aim of the present study was to evaluate potential biological markers to predict outcome from adjuvant chemotherapy. Therefore, we have performed an integrative analysis of the expression of miR-21, miR-29b, miR-34a/b/c, miR-155 and let-7a-2 in a cohort of PDAC patients, with known pathological and treatment characteristics. Additionally, we have investigated expression of 20 known potential protein markers and targets for therapy, involved in PDAC progression and prognosis (See Table S1 for a complete overview of the 27 biological and 9 clinicopathological factors used in the study) [6] , [13] . Since miR-21 expression status emerged as the single most predictive biomarker for treatment outcome from all factors evaluated in adjuvant-treated patients, further analysis of miR-21 expression was performed in a second cohort of 45 patients, all treated with adjuvant therapy. This independent set confirmed the significant association of miR-21 expression status with both survival and disease-free survival. In addition, the association of low miR-21 expression with benefit from adjuvant treatment was supported by in vitro data showing the increased chemosensitivity of PDAC cells after transfection with anti-miR-21. METHODS Two hundred forty five patients who underwent pancreatic cancer resection with the final diagnosis of pancreatic cancer

Read the complete text